Clinical Manifestations and Risk Factors Influencing Eradication of Extensive Multidrug-resistant Acinetobacter baumannii from the Respiratory Tract

Tai Chin Hsieh, Shio Shin Jean, Fu Lun Chen, Tsong Yih Ou, Giueng Chueng Wang, Wen Sen Lee

Research output: Contribution to journalArticle

Abstract

Purpose: Extensive multidrug-resistant Acinetobacter baumannii (XDRAB) has increasingly emerged as one of the most difficult bacteria to treat in the healthcare setting. In this study, we intended to evaluate the factors affecting eradicating XDRAB from the respiratory tract, clinical manifestations, and treatment outcomes. Methods: We retrospectively reviewed the medical records of patients who had XDRAB isolated from the respiratory tract in our medical center from January 1, 2012 to February 28, 2013. Results: In total, 87 patients were included in this study. Eradication was achieved in 69 patients (79.3%). The factors that negatively affect eradication of XDRAB by aerosolized colistin therapy for two weeks included: (1) receiving noninvasive mechanical ventilation; (2) being infected/colonized during residency in long-term care facilities; and (3) receiving combination therapy with intravenous tigecycline. The 30-day mortality in patients with versus without eradication was 26.1% versus 55.6%, respectively (. p

Original languageEnglish
Pages (from-to)213-216
Number of pages4
JournalJournal of Experimental and Clinical Medicine(Taiwan)
Volume6
Issue number6
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Acinetobacter baumannii
Respiratory System
Colistin
Noninvasive Ventilation
Long-Term Care
Internship and Residency
Artificial Respiration
Medical Records
Bacteria
Delivery of Health Care
Mortality
Therapeutics

Keywords

  • Colistin
  • Nosocomial infection
  • Pneumonia
  • Tigecycline

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{38fcdd46c82247f5b6db2994887c0d6b,
title = "Clinical Manifestations and Risk Factors Influencing Eradication of Extensive Multidrug-resistant Acinetobacter baumannii from the Respiratory Tract",
abstract = "Purpose: Extensive multidrug-resistant Acinetobacter baumannii (XDRAB) has increasingly emerged as one of the most difficult bacteria to treat in the healthcare setting. In this study, we intended to evaluate the factors affecting eradicating XDRAB from the respiratory tract, clinical manifestations, and treatment outcomes. Methods: We retrospectively reviewed the medical records of patients who had XDRAB isolated from the respiratory tract in our medical center from January 1, 2012 to February 28, 2013. Results: In total, 87 patients were included in this study. Eradication was achieved in 69 patients (79.3{\%}). The factors that negatively affect eradication of XDRAB by aerosolized colistin therapy for two weeks included: (1) receiving noninvasive mechanical ventilation; (2) being infected/colonized during residency in long-term care facilities; and (3) receiving combination therapy with intravenous tigecycline. The 30-day mortality in patients with versus without eradication was 26.1{\%} versus 55.6{\%}, respectively (. p",
keywords = "Colistin, Nosocomial infection, Pneumonia, Tigecycline",
author = "Hsieh, {Tai Chin} and Jean, {Shio Shin} and Chen, {Fu Lun} and Ou, {Tsong Yih} and Wang, {Giueng Chueng} and Lee, {Wen Sen}",
year = "2014",
month = "12",
day = "1",
doi = "10.1016/j.jecm.2014.10.003",
language = "English",
volume = "6",
pages = "213--216",
journal = "Journal of Experimental and Clinical Medicine",
issn = "1878-3317",
publisher = "Elsevier Taiwan LLC",
number = "6",

}

TY - JOUR

T1 - Clinical Manifestations and Risk Factors Influencing Eradication of Extensive Multidrug-resistant Acinetobacter baumannii from the Respiratory Tract

AU - Hsieh, Tai Chin

AU - Jean, Shio Shin

AU - Chen, Fu Lun

AU - Ou, Tsong Yih

AU - Wang, Giueng Chueng

AU - Lee, Wen Sen

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Purpose: Extensive multidrug-resistant Acinetobacter baumannii (XDRAB) has increasingly emerged as one of the most difficult bacteria to treat in the healthcare setting. In this study, we intended to evaluate the factors affecting eradicating XDRAB from the respiratory tract, clinical manifestations, and treatment outcomes. Methods: We retrospectively reviewed the medical records of patients who had XDRAB isolated from the respiratory tract in our medical center from January 1, 2012 to February 28, 2013. Results: In total, 87 patients were included in this study. Eradication was achieved in 69 patients (79.3%). The factors that negatively affect eradication of XDRAB by aerosolized colistin therapy for two weeks included: (1) receiving noninvasive mechanical ventilation; (2) being infected/colonized during residency in long-term care facilities; and (3) receiving combination therapy with intravenous tigecycline. The 30-day mortality in patients with versus without eradication was 26.1% versus 55.6%, respectively (. p

AB - Purpose: Extensive multidrug-resistant Acinetobacter baumannii (XDRAB) has increasingly emerged as one of the most difficult bacteria to treat in the healthcare setting. In this study, we intended to evaluate the factors affecting eradicating XDRAB from the respiratory tract, clinical manifestations, and treatment outcomes. Methods: We retrospectively reviewed the medical records of patients who had XDRAB isolated from the respiratory tract in our medical center from January 1, 2012 to February 28, 2013. Results: In total, 87 patients were included in this study. Eradication was achieved in 69 patients (79.3%). The factors that negatively affect eradication of XDRAB by aerosolized colistin therapy for two weeks included: (1) receiving noninvasive mechanical ventilation; (2) being infected/colonized during residency in long-term care facilities; and (3) receiving combination therapy with intravenous tigecycline. The 30-day mortality in patients with versus without eradication was 26.1% versus 55.6%, respectively (. p

KW - Colistin

KW - Nosocomial infection

KW - Pneumonia

KW - Tigecycline

UR - http://www.scopus.com/inward/record.url?scp=84916200536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84916200536&partnerID=8YFLogxK

U2 - 10.1016/j.jecm.2014.10.003

DO - 10.1016/j.jecm.2014.10.003

M3 - Article

AN - SCOPUS:84916200536

VL - 6

SP - 213

EP - 216

JO - Journal of Experimental and Clinical Medicine

JF - Journal of Experimental and Clinical Medicine

SN - 1878-3317

IS - 6

ER -